These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36254086)

  • 21. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.
    Nojima Y; Yasuoka Y; Kume K; Adachi H; Hattori S; Matsutera R; Kohama Y; Sasaki T
    Coron Artery Dis; 2014 Dec; 25(8):638-44. PubMed ID: 25076360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictor of in-stent restenosis in patients with drug-eluting stent (PRIDE)- a retrospective cohort study.
    Gupta PK; Balachander J
    Clin Investig Arterioscler; 2021; 33(4):184-194. PubMed ID: 33622608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
    Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
    Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
    Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions.
    Watanabe Y; Takagi K; Naganuma T; Kawamoto H; Fujino Y; Ishiguro H; Tahara S; Kurita N; Hosawa K; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Aug; 240():108-113. PubMed ID: 28476515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value Analysis of in-Stent Restenosis Within Three Years in Older Acute Coronary Syndrome Patients: A Two-Center Retrospective Study.
    Zhou J; Chai D; Dai Y; Wang A; Yan T; Lu S
    Clin Appl Thromb Hemost; 2022; 28():10760296221107888. PubMed ID: 35706375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistant in-stent restenosis in the drug eluting stent era.
    Theodoropoulos K; Mennuni MG; Dangas GD; Meelu OA; Bansilal S; Baber U; Sartori S; Kovacic JC; Moreno PR; Sharma SK; Mehran R; Kini AS
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):777-785. PubMed ID: 27184223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis.
    Zhao L; Zhu W; Zhang X; He D; Guo C
    BMC Cardiovasc Disord; 2017 Jan; 17(1):16. PubMed ID: 28061808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes at 1 Year of Non-Left Main Trunk Bifurcation Lesions Treated With a 2-Stent Strategy Using Newer-Generation Everolimus-Eluting Stents.
    Okabe K; Ohya M; Ikuta A; Takamatsu M; Osakada K; Shimada T; Miura K; Kubo S; Tada T; Tanaka H; Fuku Y; Katoh H; Kadota K
    Circ J; 2021 Oct; 85(11):1972-1980. PubMed ID: 34349075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography.
    Wan YL; Tsay PK; Chen CC; Juan YH; Huang YC; Chan WH; Wen MS; Hsieh IC
    Int J Cardiovasc Imaging; 2016 Jun; 32 Suppl 1():105-15. PubMed ID: 27106698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
    Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
    Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Insulin Resistance on Neointimal Tissue Proliferation after 2nd-Generation Drug-Eluting Stent Implantation.
    Komatsu T; Yaguchi I; Komatsu S; Nakahara S; Kobayashi S; Sakai Y; Taguchi I
    Tex Heart Inst J; 2015 Aug; 42(4):327-32. PubMed ID: 26413014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation.
    Zhao J; Wang X; Wang H; Zhao Y; Fu X
    Ir J Med Sci; 2020 Aug; 189(3):907-915. PubMed ID: 31989420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
    Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
    Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.